An observational study in Migraine, Worker Health and Sensitization, sponsored by Bozok University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bozok University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Migraine Disorders with a site in Turkey — 20 open to participants now, 25 under way, 3 of them phase 3. Migraine Disorders · Turkey.
Among the 92 studies in Migraine Disorders with a site in Turkey, this one is the 6th largest by enrollment of the 23 observational ones that give a count, is one of 9 that started in 2026, is one of 23 observational ones, and was the 86th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →20 of the 92 studies in Migraine Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–55
Bozok University · Sites in Turkey
Ages 18–65
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–55 · Healthy volunteers
Mustafa Kemal University · Sites in Turkey
Ages 18–55
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 73 across the 69 interventional studies, 130 across the 23 observational. Of the 63 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 92 have an industry lead sponsor. The 10 most frequent:
Bozok University is the lead sponsor of 54 studies on the registry; 9 are open to participants now.
Bozok University has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Migraine Disorders with a site in Turkey that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
| NCT06468189Istanbul Medipol University HospitalClinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine | 2026-11 |
| NCT07261384Hacettepe University"Personalized Physiotherapy for Migraine: Effects on Pain, Fatigue, and Physical Function" | 2027-01-30 |
| NCT07657377Ankara Yildirim Beyazıt UniversityThe Effects of Physiotherapy in Migraine | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Migraine Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a common neurological disease causing significant disability worldwide, with an estimated global prevalence of 14.4%. It represents a significant individual and societal burden, particularly for working-age individuals, as it can significantly impact work performance, productivity, and daily living activities. Migraine is not merely a headache; it is characterized by increased excitability of neurons in the central nervous system, leading to hypersensitivity to pain. Central sensory mechanisms are thought to play a role in the pathophysiology and chronicity of migraine, causing increased pain sensitivity, allodynia, and potentially related to musculoskeletal pain. Furthermore, psychosocial factors and work stress have been identified as significant factors associated with both headaches and musculoskeletal pain. Literature indicates that neck pain is common in individuals with migraine headaches; in fact, neck pain is twice as frequent in patients with chronic migraine headaches compared to those with episodic migraine. While evidence regarding back pain is limited, it has been shown that individuals with chronic headaches report back pain more frequently.
In modern work environments, sedentary work and prolonged computer use are increasing. Prolonged sitting, improper ergonomics, and repetitive movements are considered significant risk factors for musculoskeletal problems. This can lead to pain and functional limitations, particularly in the neck, shoulders, and back. Although there has been an increase in working from home, especially after the pandemic, the time spent at a desk is still similar to that spent in the workplace. It is stated that static muscle activity and improper postures maintained during prolonged computer use can lead to increased strain on cervical and upper extremity muscles, exacerbating musculoskeletal symptoms. Literature reports that headaches and neck pain are common among individuals who work at desks; for example, a study of office workers reported that approximately 80% of individuals with headaches also experienced neck pain. Furthermore, high workload, time pressure, and psychosocial stress factors have been shown to be associated with both headaches and musculoskeletal pain in individuals who work at desks. Therefore, desk-based work conditions are considered a significant environmental factor that may play a role in the onset or exacerbation of migraine and musculoskeletal symptoms. Despite this, studies examining musculoskeletal symptoms, central sensitivity, and work stress together in desk-bound migraine patients are limited in the literature. Most studies have only examined individuals with headaches or evaluated musculoskeletal findings in limited areas. Therefore, studies comparing desk-bound migraine patients with non-migraine-bound desk-bound individuals could fill a significant gap in the literature. In this context, it is believed that the planned study will contribute to a better understanding of the possible relationships between migraine and musculoskeletal symptoms, help develop protective and rehabilitative approaches to the work environment, and benefit individuals exposed to musculoskeletal risks in desk-bound work, within the scope of Sustainable Development Goals 3: ensure healthy lives and promote well-being for all at all ages. The aim of this study is to compare central sensitization, work-related stress levels, and musculoskeletal symptoms in desk-based workers according to the presence of migraine and to examine the relationships among these variables.
Gaziantep City Hospital, Department of Neurology, Gaziantep, Türkiye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Episodic migraine is a neurological condition characterized by recurrent, moderate-to-severe headaches occurring on fewer than 15 days per month. Attacks typically last 4 to 72 hours and are often accompanied by nausea, vomiting, and light/sound sensitivity. Treatment involves acute, on-demand medication and preventative strategies to reduce attack frequency.
Chronic migraine is defined by having 15 or more headache days per month for over three months, with at least eight of those days meeting migraine criteria. Symptoms include moderate-to-severe throbbing pain, nausea, vomiting, and extreme sensitivity to light, sound, or smell.
Individuals without a diagnosis of episodic or chronic migraine, as well as individuals without other headache diagnoses.
Central Sensitization Inventory
The Central Sensitization Inventory (CSI) measures somatic and emotional symptoms common in central sensitization syndrome. Section A measures 25 symptoms with 5 response options (0 to 4). The total score ranges from 0 to 100. Section B asks patients whether they have previously been diagnosed with preliminary specific CSI conditions
Time frame: Day 1
Headache Intensity
The Numerical Pain Rating Scale (NPRS) consists of pain levels where the person indicates the pain they are currently experiencing with a vertical line on a plane. The pain felt by the person is given on a scale of 0-10, "0: no pain", "10: I feel very severe pain".
Time frame: Day 1
Disability
The Migraine Disability Assessment (MIDAS) questionnaire evaluates the last 3 months of disability and consists of a 5-item self-administered test covering disability at work/school, household chores, family and social or leisure activities. The total number of days missed in these activities is the total score and classifies the disability as minimal disability (0-5 points), mild disability (6-10 points), moderate disability (11-20 points), or severe disability (≥21)
Time frame: Day 1
Work-Related Stress
The General Work Stress Scale (GWSS) is a 9-item questionnaire that measures how much stress individuals experience in the workplace. It consists of 5 Likert-type items (Never=0, Rarely=1, Sometimes=2, Mostly=3, Always=4). Higher scores indicate increased workplace stress.
Time frame: Day 1
Musculoskeletal Pain Symptoms
The Nordic Musculoskeletal Questionnaire (NMSQ) is a standardized, subjective data collection tool used to identify musculoskeletal disorders and pain in different areas of the body (low back, neck, shoulders, etc.). Individuals are asked whether they have experienced pain/discomfort in the relevant areas in the last 1 year or the last 7 days, usually coded as "Yes/No". The total number of painful areas is determined
Time frame: Day 1
Headache Impact
The Headache Impact Test-6 (HIT-6) is a questionnaire for headaches that assesses vitality, pain, psychological distress, sociability, role, and cognitive functioning. Each item is scored on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, 13=always). The total score is determined by summing the scores on all six items and ranges from 36 to 78 points. (≤49 = little/no impact, 50-55 = some impact, 56-59 = significant impact, and 60-78 = serious impact).
Time frame: Day 1
Demographic and Clinic Evaluations
Demographic and clinical information such as sex, age, weight, height, education level, occupation, medical history, family history, number of years diagnosed with migraine (if any), migraine triggers, symptoms experienced during attacks, number of headache days per month, number of headache attacks per month, duration of attacks, localization of headaches, and sitting time at a desk will be recorded for all patients.
Time frame: Day 1
Plan to share: Undecided — The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.
Ran from Apr 2026 to primary completion in May 2026, 0 months.
Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's 0 months is below that.
Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bozok University